Published: 3 June 2020
Author(s): Ugo Paliani, Andrea Cardona
Issue: August 2020
Section: Editorial

The absence of an effective treatment against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection has led clinicians to redirect drugs that are known to be effective for other medical conditions to the treatment of Covid-19. Chloroquine and hydroxychloroquine are widely used in the treatment of malaria and rheumatic diseases, and they have been suggested as effective treatments for Covid-19 on the grounds of both anti-inflammatory and antiviral effects [1–4]. Mounting data suggest that Covid-19 is burdened by a higher risk of arrhythmic events, with important implications for survival [5].

Newsletters

Stay informed on our latest news!